Adelaiye-Ogala et al. (2017) reported that increased EZH2 was associated with sunitinib resistance through redistribution in RCC cells, decreasingly binding to the PTK2 gene, which encodes the FAK, and increasingly binding to DAB2IP and PTPN2, which act as tumor suppressors to inhibit RAS/RAF/ERK and P13K/AKT signaling pathways. The gene discussed is AKT1; the disease is renal cell adenocarcinoma.